French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version

Cottin, Vincent; Bonniaud, Philippe; Cadranel, Jacques; Crestani, Bruno; Jouneau, S.; Marchand-Adam, S.; Nunès, Hilario; Wémeau-Stervinou, Lidwine; Blanchard, Élodie; Borie, R.; Bourdin, Arnaud; Chenivesse, Cécile; Clément, Annick; Gomez, E.; Gondouin, Anne; Hirschi, Sandrine; Lebargy, F.; Marquette, Charles‐Hugo; Montani, David; Prévôt, Grégoire; Quétant, S.; Reynaud‐Gaubert, Martine; Sanchez, Olivier; Trumbic, B.; Berkani, K; Brillet, Pierre-Yves; Campana, M.; Chalabreysse, Lara; Chatté, G; Debieuvre, D.; Ferretti, Gilbert; Fourrier, Jean-Michel; Just, N.; Kambouchner, Marianne; Legrand, Bertrand; Guillou, F. Le; L’Huillier, Jean-Pierre; Mehdaoui, A; Naccache, Jean‐Marc; Paganon, C.; Rémy‐Jardin, Martine; Terrioux, P.

doi:10.1016/j.resmer.2022.100948

Cited by 8 publications

(10 citation statements)

References 551 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient management for ADR depends on the severity of the ADR and contains an inherent degree of subjectivity [27][28][29][30]. An update of the French IPF guidelines provide information on the prevention and management related to some expected ADRs of pirfenidone and nintedanib (for gastrointestinal and metabolic/nutritional disorders, hepatic disorders and skin disorders) [31]. Overall, the decision to keep a patient on antifibrotic therapy should be specific to each patient.…”

Section: Discussionmentioning

confidence: 99%

“…The summary of product characteristics of nintedanib does not contraindicate its use in patient with high risk of cardiovascular disorders but advises "caution" [34], which, from a pragmatic clinical point of view does not help the physician in charge of the patient... The French recommendations for managing IPF indicate also that nintedanib should be used with caution in IPF patients on anticoagulants, or high-dose antiplatelet therapy, or who are at risk of ischemic heart disease [31,40]. It is recommended in such patients to avoid nintedanib as first line treatment in IPF patients [31].…”

Section: Cardiovascularmentioning

confidence: 99%

“…The French recommendations for managing IPF indicate also that nintedanib should be used with caution in IPF patients on anticoagulants, or high-dose antiplatelet therapy, or who are at risk of ischemic heart disease [31,40]. It is recommended in such patients to avoid nintedanib as first line treatment in IPF patients [31]. As a reminder, over half our patients were at high risk of cardiovascular disorders, about 57% of those on nintedanib and 62% of those on ACCEPTED MANUSCRIPT / CLEAN COPY pirfenidone.…”

Section: Cardiovascularmentioning

confidence: 99%

See 2 more Smart Citations

Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients

Fournier

Jouneau²,

Bouzillé³

et al. 2022

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Cardiovascularmentioning

confidence: 99%

Section: Cardiovascularmentioning

confidence: 99%

See 1 more Smart Citation

Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients

Fournier

Jouneau²,

Bouzillé³

et al. 2022

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…We reviewed relevant recommendations related to the 24 clinical/diagnostic scenarios previously published by radiology and specialty societies, including: the Canadian Association of Radiologists, 9 the American College of Radiology, [10][11][12][13][14][15][16][17][18][19] the American Thoracic Society and Infectious Diseases Society of America, 20 the CHEST Expert Panel, [21][22][23] the Emergency Medicine Association of Turkey/Turkish Thoracic Society, 24 the European Respiratory Society, 25 the Fleischner Society, 26,27 the French Language Pulmonology Society, 28 the German S3 guideline, 29 the Indian Chest Society National College of Chest Physicians, 30 the Indian Society of Anesthaesiologists, 31 the Italian intersociety consensus, 32,33 the Korean guideline, 34 the National Institute for Health and Clinical Excellence, 35 the Polish recommendations for lung ultrasound in internal medicine, 36 the S2K guideline, 37 the combined guideline by the Société Française de Médecine d'Urgence, the Société de Réanimation de Langue Française and the French Group for Pediatric Intensive Care and Emergencies, 38 the Spanish Society of Medical Oncology, 39 and the Royal College of Radiologists. 40 Recommendations are presented in 3 tables: Non-specific chest pain, long-term care, and hospital-based scenarios (Table 2), Upper respiratory tract infections, asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and chronic cough scenarios (Table 3), Pneumothorax, pleural effusion, hemoptysis, chronic dyspnea, interstitial lung disease, lung nodule, mediastinal lesion, mediastinal lymphadenopathy, and elevated diaphragm scenarios (...…”

Section: Recommendations Additional Details Of the Included Guideline...mentioning

confidence: 99%

Canadian Association of Radiologists Thoracic Imaging Referral Guideline

Hamel,

Avard,

Belanger

et al. 2023

Can Assoc Radiol J

View full text Add to dashboard Cite

The Canadian Association of Radiologists (CAR) Thoracic Expert Panel consists of radiologists, respirologists, emergency and family physicians, a patient advisor, and an epidemiologist/guideline methodologist. After developing a list of 24 clinical/diagnostic scenarios, a rapid scoping review was undertaken to identify systematically produced referral guidelines that provide recommendations for one or more of these clinical/diagnostic scenarios. Recommendations from 30 guidelines and contextualization criteria in the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) for guidelines framework were used to develop 48 recommendation statements across the 24 scenarios. This guideline presents the methods of development and the referral recommendations for screening/asymptomatic individuals, non-specific chest pain, hospital admission for non-thoracic conditions, long-term care admission, routine pre-operative imaging, post-interventional chest procedure, upper respiratory tract infection, acute exacerbation of asthma, acute exacerbation of chronic obstructive pulmonary disease, suspect pneumonia, pneumonia follow-up, immunosuppressed patient with respiratory symptoms/febrile neutropenia, chronic cough, suspected pneumothorax (non-traumatic), clinically suspected pleural effusion, hemoptysis, chronic dyspnea of non-cardiovascular origin, suspected interstitial lung disease, incidental lung nodule, suspected mediastinal lesion, suspected mediastinal lymphadenopathy, and elevated diaphragm on chest radiograph.

show abstract

“…French practical guidelines (2022) [86] • Minimum MDT participants: pulmonologists, radiologists and pathologists with experience in the field of interstitial pneumonia • MDT discussion should take place in an expert or specialised centre…”

Section: Ipfmentioning

confidence: 99%

Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives

et al. 2022

Self Cite

View full text Add to dashboard Cite

Multidisciplinary team (MDT) meetings, involving the integrated collaboration of healthcare professionals, are increasingly used in clinical practice to inform the diagnosis and treatment of interstitial lung diseases (ILDs). Over time, the assessment of patients with ILD has transitioned from discussions among clinicians, radiologists and pathologists to the inclusion of a broader range of clinical data and specialist expertise. Studies have shown that a multidisciplinary approach can have many benefits for the clinical care of patients with ILD by improving the diagnostic confidence for different ILDs and guiding treatment decisions. The utility of MDT discussions for diagnosis, monitoring disease progression and management decisions, will need to be considered based on how it is best positioned in the diagnostic and therapeutic process, as well as the practicality and challenges of its use. There are also uncertainties and heterogeneity concerning the optimal practices of MDT meetings in ILD care. In this review, we describe recent developments refining the approach to MDTs in clinical practice, including who should be involved in the MDTs, when it is most needed, their use in patient management, challenges in their implementation, and ongoing controversies in the field that need further research.

show abstract

French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis – 2021 update. Full-length version

Cited by 8 publications

References 551 publications

Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients

Real-world safety profiles of pirfenidone and nintedanib in idiopathic pulmonary fibrosis patients

Canadian Association of Radiologists Thoracic Imaging Referral Guideline

Multidisciplinary teams in the clinical care of fibrotic interstitial lung disease: current perspectives

Contact Info

Product

Resources

About